Get started
Hemostemix Inc
Long

$HMTXF witnesses the return of intellectual property to the comp

25

In the very recent news release, the company announces that it possesses the entirety of its intellectual property, including all HS 12-01 Phase II clinical path information and all authentic information from Hemostemix Israel.
InvestorRelations-1
Also on:
Fundamental AnalysistradingtradingsignalstradingstrategiesTrend Analysis

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Fundamental AnalysistradingtradingsignalstradingstrategiesTrend Analysis
InvestorRelations-1
Also on:

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.